Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming
Open Access
- 13 March 2025
- journal article
- basic and-translational-cancer-immunology
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e011030
Abstract
Background Strategies to improve the therapeutic efficacy of cancer immunotherapy with immune checkpoint inhibitors include targeting additional immunosuppressive compartments in the tumor microenvironment (TME). Inhibitory macrophages (Mφ) can be one of the most abundant immune cells in the TME associated with poor prognosis. However, to date, selective Mφ depletion strategies as a cancer immunotherapy have not been successful in clinical trials. Macrophage Receptor with Collagenous Structure (MARCO) is one of a family of class-A scavenger receptors expressed by Mφ in the TME and is one of the most upregulated transcripts in dendritic cells (DC) following their ex vivo uptake of dead tumor cells. The clinical significance of MARCO expression in the TME is not fully understood. Methods The therapeutic potential of targeting MARCO by an anti-murine MARCO (ED31, clone ED31) monoclonal antibody, which inhibits ligand-binding to MARCO, was explored in combination with anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) or anti-programmed cell death protein-1 (anti-PD-1) in C57BL/6J mice bearing B16F10 or Pan02 tumors. The mechanism by which ED31 impacts the TME was investigated by flow cytometry in the different treatment arms. The contribution of Mφ was assessed by both in vivo depletion and in vitro functional assays. Chemokine production was measured by a bead-based multiplex assay. Results ED31 enhanced antitumor efficacy of anti-CTLA-4, but not of anti-PD-1. Analysis of the TME revealed that adding ED31 to anti-CTLA-4 substantially increased immune cell infiltration, including mature conventional DC recruitment, that was due to a switch to M1-pattern chemokines by Mφ. Mφ depletion completely abrogated both the increase in immune cell infiltration and chemokine production, and abolished the antitumor efficacy of the combination therapy. Conclusions Targeting MARCO as an additional checkpoint in the TME can offer a strategy to improve the antitumor efficacy of anti-CTLA-4 through a mechanism involving Mφ reprogramming rather than their depletion.Keywords
Funding Information
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (N/A)
- Chris Sullivan Fund (N/A)
- CJG Fund (N/A)
- Norges Idrettshøgskole (1R01 CA148995)
- Norges Idrettshøgskole (1R01 CA184845)
- Norges Idrettshøgskole (P30 CA076292)
- Norges Idrettshøgskole (P50 CA168536)
- V Foundation for Cancer Research (N/A)
This publication has 50 references indexed in Scilit:
- The cancer-immunity cycle: Indication, genotype, and immunotypeImmunity, 2023
- Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumorsImmunity, 2021
- Expression of scavenger receptor MARCO defines a targetable tumor‐associated macrophage subset in non‐small cell lung cancerInternational Journal of Cancer, 2018
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune ControlCell, 2018
- Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and MetastasisCell Reports, 2016
- Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array ProfilingThe American Journal of Pathology, 2011
- Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activityCancer Immunology, Immunotherapy, 2010
- Extracellular matrix signature identifies breast cancer subgroups with different clinical outcomeThe Journal of Pathology, 2008
- Dendritic cells and the control of immunityNature, 1998
- Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophagesCell, 1995